

## Hemovigilance Module Adverse Reaction Transfusion Associated Graft vs. Host Disease

*Required for savin	g						
*Facility ID#:	NHSN Adverse Reaction #:						
Patient Information							
*Patient ID: *Date of Birth://							
*Sex:MF							
Social Security #:	Secondary ID: _	Medicare #:					
Last Name:	First Name:	Middle Name:					
Ethnicity (Specify):	Hispanic or Latino	spanic or Latino					
Race (Select all that apply):	American Indian or Asian Alaska Native Native Hawaiian or White Pacific Islander	Black or African       Middle Eastern or North         American       African         Unknown       Declined to respond					
Preferred Language (	Specify from the list provided):	Interpreter Needed: Yes No					
*Blood Group:       A-       A+       B-       B+       AB+       O-       O+       Blood type not done <ul> <li>Transitional ABO / Rh +</li> <li>Transitional ABO / Rh -</li> <li>Transitional ABO / Transitional Rh</li> <li>Group A/Transitional Rh</li> <li>Group B/Transitional Rh</li> <li>Group O/Transitional Rh</li> <li>Group AB/Transitional Rh</li> <li>Group AB/Transitio</li></ul>							
Patient Medical Hi	istory						
List the patient's ac	dmitting diagnosis. <i>(Use ICD-10 D</i>	agnostic codes/descriptions)					
Code:	Description:						
Code:	Description:						
Code:	Description:						
List the patient's underlying indication for transfusion. (Use ICD-10 Diagnostic codes/descriptions)							
Code:	Description:						
Code:							
Code:	Description:						
List the patient's comorbid conditions at the time of the transfusion related to the adverse UNKNOWN reaction. (Use ICD-10 Diagnostic codes/descriptions)							
Code:	Description:						
Code:	Description:						
Code:	Description:						

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)). CDC 57.316 Rev. 3, v9.2

Public reporting burden of this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering, and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS H21-8, Atlanta, GA 30333, ATTN: PRA (0920-0666).



List the nationt's relevant n	nadical presedure including past presedures and presedures to be					
List the patient's relevant medical procedure including past procedures and procedures to be performed during the current hospital or outpatient stay. (Use ICD-10 Procedure ONONE NONE NONE						
Code:	_ Description:					
Code:	_ Description:					
Code:	_ Description:					
Additional Information						
Transfusion History						
Has the patient received a	previous transfusion?	IKNOWN				
Blood Product:	] WB 🔄 RBC 🔄 Platelet 🔄 Plasma 🗌 Cryoprecipitate	Granulocyte				
Date of Transfusion:						
·	e reaction transfusion-related?					
	n about the transfusion adverse reaction.	<u> </u>				
	erse reaction:					
- -	ify					
Reaction Details		•				
	_// *Time reaction occurred:: Time u	unknown				
*Facility location where pati						
Is this reaction associated with an incident? Yes No If Yes, Incident #:						
Investigation Results						
Investigation Results * Transfusion associated	d graft vs. host disease (TA-GVHD)					
Investigation Results *   Transfusion associated *Case Definition	d graft vs. host disease (TA-GVHD)					
Investigation Results *   Transfusion associated *Case Definition						
Investigation Results  Transfusion associated  Case Definition Did patient receive non-in Check all that occurred v	d graft vs. host disease (TA-GVHD)					
Investigation Results  Transfusion associated  Case Definition Did patient receive non-in Check all that occurred w Clinical syndrome	d graft vs. host disease (TA-GVHD) radiated blood product(s) in the two months preceding the reaction? within 2 days to 6 weeks after cessation of transfusion:	Yes No				
Investigation Results  Transfusion associated  Case Definition Did patient receive non-in Check all that occurred v Clinical syndrome Clinical syndrom	d graft vs. host disease (TA-GVHD) radiated blood product(s) in the two months preceding the reaction? within 2 days to 6 weeks after cessation of transfusion: e characteristics:	☐ Yes ☐ No ☐ Pancytopenia				
Investigation Results  Transfusion associated  Case Definition Did patient receive non-in Check all that occurred v Clinical syndrome Clinical syndrom Liver dysfunc	d graft vs. host disease (TA-GVHD) radiated blood product(s) in the two months preceding the reaction? within 2 days to 6 weeks after cessation of transfusion: e characteristics: Diarrhea Fever Hepatomegaly tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin)	☐ Yes ☐ No ☐ Pancytopenia ☐ Marrow aplasia				
Investigation Results    Transfusion associated    Case Definition  Did patient receive non-in  Check all that occurred v  Clinical syndrome  Clinical syndrom  Liver dysfunc  Characteristic	d graft vs. host disease (TA-GVHD) radiated blood product(s) in the two months preceding the reaction? within 2 days to 6 weeks after cessation of transfusion: e characteristics:	☐ Yes ☐ No ☐ Pancytopenia ☐ Marrow aplasia 5 to extremities and				
Investigation Results    Transfusion associated    Case Definition  Did patient receive non-in  Check all that occurred v  Clinical syndrome  Clinical syndrom  Liver dysfunc  Characteristic	d graft vs. host disease (TA-GVHD) radiated blood product(s) in the two months preceding the reaction? within 2 days to 6 weeks after cessation of transfusion: e characteristics: Diarrhea Fever Hepatomegaly tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) c rash: erythematous, maculopapular eruption centrally that spreads	☐ Yes ☐ No ☐ Pancytopenia ☐ Marrow aplasia 5 to extremities and				
Investigation Results	d graft vs. host disease (TA-GVHD) radiated blood product(s) in the two months preceding the reaction? within 2 days to 6 weeks after cessation of transfusion: e characteristics: Diarrhea Fever Hepatomegaly tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) c rash: erythematous, maculopapular eruption centrally that spreads	☐ Yes ☐ No ☐ Pancytopenia ☐ Marrow aplasia 5 to extremities and				
Investigation Results	d graft vs. host disease (TA-GVHD) radiated blood product(s) in the two months preceding the reaction? within 2 days to 6 weeks after cessation of transfusion: e characteristics: Diarrhea Fever Hepatomegaly tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) c rash: erythematous, maculopapular eruption centrally that spreads cases, progress to generalized erythroderma and hemorrhagic bullou	☐ Yes ☐ No ☐ Pancytopenia ☐ Marrow aplasia 5 to extremities and				
Investigation Results	d graft vs. host disease (TA-GVHD) radiated blood product(s) in the two months preceding the reaction? within 2 days to 6 weeks after cessation of transfusion: e characteristics: Diarrhea Fever Hepatomegaly tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) c rash: erythematous, maculopapular eruption centrally that spreads cases, progress to generalized erythroderma and hemorrhagic bullou logical appearance of skin or liver biopsy. not done.	<ul> <li>Yes □ No</li> <li>Pancytopenia</li> <li>Marrow aplasia</li> <li>to extremities and</li> </ul>				
Investigation Results	d graft vs. host disease (TA-GVHD) radiated blood product(s) in the two months preceding the reaction? within 2 days to 6 weeks after cessation of transfusion: e characteristics: Diarrhea Fever Hepatomegaly tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) c rash: erythematous, maculopapular eruption centrally that spreads cases, progress to generalized erythroderma and hemorrhagic bullou logical appearance of skin or liver biopsy. not done.	☐ Yes ☐ No ☐ Pancytopenia ☐ Marrow aplasia 5 to extremities and				
Investigation Results	d graft vs. host disease (TA-GVHD)         radiated blood product(s) in the two months preceding the reaction?         within 2 days to 6 weeks after cessation of transfusion:         e characteristics:       Diarrhea         Fever       Hepatomegaly         tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin)         c rash: erythematous, maculopapular eruption centrally that spreads         cases, progress to generalized erythroderma and hemorrhagic bullou         logical appearance of skin or liver biopsy.         not done.         s: (check all that apply)	☐ Yes ☐ No ☐ Pancytopenia ☐ Marrow aplasia 5 to extremities and				
Investigation Results	d graft vs. host disease (TA-GVHD)         radiated blood product(s) in the two months preceding the reaction?         within 2 days to 6 weeks after cessation of transfusion:         e characteristics:       Diarrhea         Fever       Hepatomegaly         tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin)         c rash: erythematous, maculopapular eruption centrally that spreads         cases, progress to generalized erythroderma and hemorrhagic bullou         logical appearance of skin or liver biopsy.         not done.         ::       (check all that apply)         Chills/rigors       Nausea/vomiting	<ul> <li>Yes □ No</li> <li>Pancytopenia</li> <li>Marrow aplasia</li> <li>to extremities and</li> </ul>				
Investigation Results  Transfusion associated  *Case Definition Did patient receive non-in Check all that occurred w Clinical syndrome Clinical syndrom Liver dysfunc Characteristic may, in severe c Check all that apply: Characteristic histol Biopsy negative or r Other signs and symptoms Generalized: Cardiovascular:	d graft vs. host disease (TA-GVHD)         radiated blood product(s) in the two months preceding the reaction?         within 2 days to 6 weeks after cessation of transfusion:         e characteristics:       Diarrhea         Diarrhea       Fever         Hepatomegaly         tion (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin)         c rash: erythematous, maculopapular eruption centrally that spreads         cases, progress to generalized erythroderma and hemorrhagic bullou         logical appearance of skin or liver biopsy.         not done.         s:       (check all that apply)         Chills/rigors       Nausea/vomiting         Blood pressure decrease       Shock	Pancytopenia Pancytopenia Marrow aplasia to extremities and us formation.				

NHSN NATIONAL HEALTHCARE SAFETY NETWORK					Form Approved OMB No. 0920-0666 Exp. Date: 12/31/2027 www.cdc.gov/nhsn		
Hemolysis/Hemorrhage:	<ul> <li>Disseminated intravascular coagulation</li> <li>Hemoglobinemia</li> <li>Positive antibody screen</li> </ul>						
Pain:	Abdominal pain	🗌 Back pai	lank pain	Infusion site pain			
Renal:	Hematuria	Hemoglo	🗌 Oliguria				
Respiratory:	Bronchospasm	Shortness of breath					
Other: (specify)							
*Severity							
Did the patient receive or	experience any of the	following?					
No treatment requ	ired	Sympton	natic treatm	nent only			
Hospitalization, inl	cuding prolonged hospi	italization	Ľ	Life-threate	ening reaction		
Disability and/or in	capacitation	🗌 Congeni	tal anomaly	y or birth defe	ect(s) of the fetus		
Other medically in	portant conditions	Death	Death Unknown or not stated				
*Imputability							
Which best describes the relationship between the transfusion and the reaction?         No other alternative diagnoses.         Other potential causes are present (e.g., stem cell transplantation).         Alternative explanations are more likely (e.g., solid organ transplantation).         Evidence is clearly in favor of a cause other than the transfusion, but transfusion cannot be excluded.         There is conclusive evidence beyond reasonable doubt of a cause other than the transfusion         The relationship between the adverse reaction and the transfusion is unknown or not stated.         Did the transfusion occur at your facility?       YES       NO         WBC chimerism:       WBC chimerism present       WBC chimerism not present or not done							
Module-generated Desig	Inations						
NOTE: Designations for case application based on respons	-	• •		-	igned in the NHSN		
*Do you agree with the ^Please indicate your de	<u>case definition</u> design	nation?		🗌 YES	□ NO		
* <b>Do you agree with the</b> ^Please indicate your de				☐ YES	□ NO		
*Do you agree with the ^Please indicate your de				☐ YES			
Patient Treatment							
	: <i>the type of medication)</i> Antihistamines nmunoglobulin	] Inotropes/Va avenous sterc sporin [	sopressors	'ES ☐ N s ☐ Bronch Corticosteroi	odilator Diuretics		

Form Approved       OMB No. 0920-0666         NATIONAL HEALTHCARE       Exp. Date: 12/31/2027         Www.cdc.gov/nhsn       Wolume resuscitation (Intravenous colloids or crystalloids)										
Respiratory support (Select the type of support)										
Mechanical ventilation Noninvasive ventilation Oxygen										
Renal replacement therapy (Select the type of therapy) Hemodialysis Peritoneal Continuous Veno-Venous Hemofiltration										
	ootomy									
Other Outcome	r Specify:									
*Outcome:	Death Ma	ajor or long-tern			Minor or no sec	مدامیں		t detern	nined	
Date of I		/	1 3640			luciae		n detern	inieu	
^lf re	ecipient died, relation	ship of transfus	ion to	death:						
	Definite Probable	e 🗌 Possibl	e [	Doubtful	Ruled Out		Not de	etermine	ed	
Cause o		Yes	□ Nc				_			
	autopsy performed?									
Component Details         *Was a particular unit implicated in (i.e., responsible for) the adverse reaction?										
	*Component code (check system used)	transfused at Infection and		*Unit expiration Date/Time	*Blood group			Implicat ed Unit?		
	UNIT								-	
//	ISBT-128									
:	Codabar	Entire unit Partial unit			//	🗆 A-	🗆 A+	🗆 В-	Y	
/		mL				□в+	🗆 АВ-	🗆 AB+		
:					:	0-	0+	🗆 N/A		
//	ISBT-128									
:	Codabar	Entire unit Partial unit			//	🗆 A-	🗆 A+	🗆 В-	N	
/		mL				□В+	🗆 AB-	🗌 AB+		
: I					:	0-	0+	□ N/A		
Custom Field	S									
Label				Label						
Comments										
Johnnento										